Adalta Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.13M Sell
18,572
-50
-0.3% -$2.92K 0.54% 38
2025
Q4
$1M Hold
18,622
0.45% 36
2025
Q3
$840K Sell
18,622
-150
-0.8% -$7K 0.38% 39
2025
Q2
$869K Buy
18,772
+50
+0.3% +$2.45K 0.44% 36
2025
Q1
$1.14M Sell
18,722
-100
-0.5% -$5.83K 0.61% 33
2024
Q4
$1.06M Sell
18,822
-55
-0.3% -$3.07K 0.56% 35
2024
Q3
$977K Hold
18,877
0.5% 35
2024
Q2
$784K Hold
18,877
0.43% 40
2024
Q1
$1.02M Sell
18,877
-50
-0.3% -$2.55K 0.57% 33
2023
Q4
$971K Sell
18,927
-165
-0.9% -$8.66K 0.59% 33
2023
Q3
$1.11M Sell
19,092
-135
-0.7% -$8.27K 0.76% 32
2023
Q2
$1.23M Sell
19,227
-71
-0.4% -$4.76K 0.82% 31
2023
Q1
$1.34M Hold
19,298
0.94% 28
2022
Q4
$1.39M Hold
19,298
0.98% 27
2022
Q3
$1.37M Hold
19,298
0.99% 27
2022
Q2
$1.5M Hold
19,298
0.97% 25
2022
Q1
$1.42M Hold
19,298
0.71% 31
2021
Q4
$1.2M Hold
19,298
0.55% 32
2021
Q3
$1.15M Hold
19,298
0.64% 30
2021
Q2
$1.29M Hold
19,298
0.7% 29
2021
Q1
$1.23M Buy
19,298
+250
+1% +$15.6K 0.71% 29
2020
Q4
$1.19M Hold
19,048
0.75% 30
2020
Q3
$1.15M Sell
19,048
-50
-0.3% -$3.01K 0.84% 26
2020
Q2
$1.12M Hold
19,098
0.89% 27
2020
Q1
$1.06M Sell
19,098
-1,000
-5% -$61.1K 0.97% 28
2019
Q4
$1.29M Sell
20,098
-175
-0.9% -$10K 0.81% 31
2019
Q3
$1.03M Hold
20,273
0.68% 35
2019
Q2
$919K Hold
20,273
0.6% 35
2019
Q1
$967K Hold
20,273
0.73% 35
2018
Q4
$1.05M Sell
20,273
-275
-1% -$14.8K 0.98% 29
2018
Q3
$1.28M Hold
20,548
0.91% 33
2018
Q2
$1.14M Sell
20,548
-600
-3% -$32.4K 0.8% 33
2018
Q1
$1.34M Hold
21,148
1.02% 29
2017
Q4
$1.29M Sell
21,148
-685
-3% -$42.8K 0.99% 31
2017
Q3
$1.39M Sell
21,833
-1,450
-6% -$84.7K 1.14% 31
2017
Q2
$1.3M Hold
23,283
1.05% 33
2017
Q1
$1.27M Buy
+23,283
New +$1.28M 1.07% 32

Other funds holding BMY

Adalta Capital Management's BMY Position: Q1 2026 in Review

Adalta Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 0.27% in Q1 2026, selling an estimated $2.92K and leaving 18,572 shares worth $1.13M. The position accounts for 0.54% of the portfolio, ranked #38.

Adalta Capital Management first reported a position in BMY in Q1 2017 and has held it in 37 quarters since. The position peaked at $1.5M in Q2 2022. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Adalta Capital Management held 18,572 shares of Bristol-Myers Squibb worth $1.13M as of Q1 2026.
  • Adalta Capital Management sold 50 Bristol-Myers Squibb shares in Q1 2026, an estimated $2.92K.
  • Bristol-Myers Squibb made up 0.54% of Adalta Capital Management's portfolio in Q1 2026, its #38 holding.
  • Adalta Capital Management first reported a position in Bristol-Myers Squibb in Q1 2017 and has held it in 37 quarters since.
  • Adalta Capital Management's Bristol-Myers Squibb position peaked at $1.5M in Q2 2022.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Adalta Capital Management's 13F filing for Q1 2026, filed 18 May 2026.